Journal of the Practice of Cardiovascular Sciences

REVIEW ARTICLE
Year
: 2017  |  Volume : 3  |  Issue : 3  |  Page : 133--138

Heart failure guidelines for India: Update 2017


Sandeep Seth, S Ramakrishnan, Neeraj Parekh, G Karthikeyan, Sandeep Singh, Gautam Sharma 
 Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Dr. Sandeep Seth
Department of Cardiology, All India Institute of Medical Sciences, New Delhi
India

Heart failure (HF) is a major health problem in India with a postadmission mortality of 20%–30%. Medication adherence ranges from 25% to 50%, and the tolerance of guideline-based medication is low for Indian patients. We took out guidelines on HF in 2015, and this update covers the changes which have occurred in HF management in the past 2 years. As a number of new drugs such as angiotensin receptor-neprilysin inhibitor and ivabradine have been approved for use in India, devices such as implantable cardioverter-defibrillators and cardiac resynchronization therapy are becoming more accessible and more left ventricular assist devices and transplants are being done in India, there is need for clear guidelines for the use of each which are practical for India.


How to cite this article:
Seth S, Ramakrishnan S, Parekh N, Karthikeyan G, Singh S, Sharma G. Heart failure guidelines for India: Update 2017.J Pract Cardiovasc Sci 2017;3:133-138


How to cite this URL:
Seth S, Ramakrishnan S, Parekh N, Karthikeyan G, Singh S, Sharma G. Heart failure guidelines for India: Update 2017. J Pract Cardiovasc Sci [serial online] 2017 [cited 2020 Feb 25 ];3:133-138
Available from: http://www.j-pcs.org/article.asp?issn=2395-5414;year=2017;volume=3;issue=3;spage=133;epage=138;aulast=Seth;type=0